IQVIA Research and Development Solutions shared an event on LinkedIn:
“Rethinking dose optimization in oncology trials.
Join experts from IQVIA and Sarah Cannon Research Institute on August 14 for a strategic discussion on how teams can move beyond the traditional maximum tolerated dose (MTD) paradigm to embrace innovative, model-informed strategies that align with FDA’s Project Optimus. Don’t miss it – register today!”
Sarah Cannon Research Institute shared this post, adding:
“On August 14, join leading experts from IQVIA and Sarah Cannon Research Institute as they engage in a for a forward-thinking discussion on transforming dose selection in oncology trials.
Discover how innovative trial design can improve patient outcomes and accelerate drug development.
Don’t miss this important conversation – Register now!”
More posts featuring IQVIA and Sarah Cannon Research Institute.